Relationship Between Metabolic Syndrome and Clinical Features, and Its Personal-Social Performance in Patients with Schizophrenia

Saatcioglu, Omer; Kalkan, Murat; Fıstikçı, Nurhan; Erek, Sakire; Kiliç, Kasım

doi:10.1007/s11126-015-9384-0

Cited by 7 publications

(15 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The effect of smoking was controlled for in the analyses for all but three of the studies (Pelayo-Teran, 2011, Chen et al, 2014, Sicras-Mainar et al, 2015. Two studies controlled for BMI (Saatcioglu et al, 2016, Sicras-Mainar et al, 2015.…”

Section: Discussionmentioning

confidence: 99%

“…Overall, eleven studies (Wysokinski, 2013, Takayanagi et al, 2012, Saatcioglu et al, 2016, Sicras-Mainar et al, 2015, Chen et al, 2013, Chen et al, 2014, Ogawa et al, 2011, de Nijs et al, 2016, Dickinson et al, 2008, Gonzalez, 2015, Pelayo-Teran, 2011 were selected for detailed analysis. Tables 1, 2 and 3 demonstrate a comparison of the included studies.…”

Section: Study Selectionmentioning

confidence: 99%

“…Four studies (Dickinson et al, 2008, Ogawa et al, 2011, Saatcioglu et al, 2016, Takayanagi et al, 2012 specified an upper age limit of 65, one a limit of 50 (de Nijs et al, 2016), and another specified an upper age limit of 42 (Chen et al, 2013).…”

Section: Demographicsmentioning

confidence: 99%

“…Two studies (Wysokinski, 2013, Gonzalez, 2015 used PANSS in combination with various other measures including, the Calgary Depression Scale for Schizophrenia (CDSS), Clinical Global Impressions scale (CGI) , Marder factor and Negative Symptoms Assessment for Motivation scale (NSA). One study (Saatcioglu et al, 2016) used the Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Positive and Negative Symptoms (SAPS/SANS), CDSS and Personal and Social Performance Scale (PSP). Another (Ogawa et al, 2011) used the Japanese equivalent of the BPRS as well as Global Assessment of Functioning (GAF) whereas the largest study in our analysis (Dickinson et al, 2008) only employed the use of the Repeatable Battery for the Assessment of Neuropsychological Status scale in the measurement of the cognitive effects of schizophrenia (RBANS).…”

Section: Assessment Of Disease Severitymentioning

confidence: 99%

“…Two studies (Saatcioglu et al, 2016, Sicras-Mainar et al, 2015 found that a diagnosis of metabolic syndrome was significantly associated with increased symptom severity. One (Saatcioglu et al, 2016) found that those with metabolic syndrome had significantly higher SANS and CDSS scores than those without (t=2.…”

Section: Symptom Severitymentioning

confidence: 99%

See 4 more Smart Citations

Associated illness severity in schizophrenia and diabetes mellitus: A systematic review

Perry

Salimkumar

Green

et al. 2017

Psychiatry Research

View full text Add to dashboard Cite

(2017) Associated illness severity in schizophrenia and diabetes mellitus : a systematic review. Psychiatry research. Permanent WRAP URL:http://wrap.warwick.ac.uk/89163 Copyright and reuse:The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions. Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. ResultsEleven observational studies were included in the analysis. Ten presented evidence in support of an association between schizophrenia severity and dysglycaemia. This association appeared particularly strong regarding negative symptomatology and impaired cognitive function, between which there may be some overlap. Studies examining positive symptomatology returned mixed results. ConclusionWhilst study design varied amongst the included studies, the results suggest that further work examining the effect of hyperglycaemia on schizophrenia severity may be relevant, particularly longitudinal studies assessing negative symptomatology and cognitive function. To the authors' knowledge, this is the first systematic review conducted to address this question.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Study Selectionmentioning

confidence: 99%

Section: Demographicsmentioning

confidence: 99%

Section: Assessment Of Disease Severitymentioning

confidence: 99%

Section: Symptom Severitymentioning

confidence: 99%

See 3 more Smart Citations

Associated illness severity in schizophrenia and diabetes mellitus: A systematic review

Perry

Salimkumar

Green

et al. 2017

Psychiatry Research

View full text Add to dashboard Cite

show abstract

Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups

Joseph¹,

Depp²,

Martin³

et al. 2015

Schizophrenia Research

View full text Add to dashboard Cite

Schizophrenia is characterized by physical (mainly metabolic and cardiovascular) comorbidity and shortened lifespan. High sensitivity C- reactive protein (hs-CRP), an inflammatory marker of hepatic origin linked to metabolic and cardiovascular diseases and mortality in the general population, has been reported to be elevated in people with schizophrenia. However, the relationship of hs-CRP to psychiatric and medical risk factors, after controlling for potentially confounding variables such as smoking, is not well established in schizophrenia. We assessed hs-CRP levels along with various demographic, psychiatric, and metabolic measures in 88 clinically stable outpatients with schizophrenia or schizoaffective disorder and 71 age epoch-matched comparison subjects with no history of a major psychiatric illness. hs-CRP levels were significantly higher in individuals with schizophrenia than in comparison subjects. Higher hs-CRP levels in schizophrenia group were associated with female gender, more severe negative symptoms, greater medical comorbidity, and worse metabolic risk factors including BMI, fasting glucose, and hemoglobin A1c levels. hs-CRP was not related to age, race, education, smoking status, antipsychotic dosage, or cognitive impairment. Longitudinal studies are needed to investigate the relationship between hs-CRP and long-term health outcomes including metabolic syndrome, cardiovascular disease, and mortality in schizophrenia.

show abstract

Increased risk of type 2 diabetes among the siblings of patients with schizophrenia

et al. 2019

View full text Add to dashboard Cite

BackgroundResearch suggests an association between metabolic disorders, such as type 2 diabetes mellitus (T2DM), and schizophrenia. However, the risk of metabolic disorders in the unaffected siblings of patients with schizophrenia remains unclear.MethodsUsing the Taiwan National Health Insurance Research Database, 3135 unaffected siblings of schizophrenia probands and 12,540 age-/sex-matched control subjects were included and followed up to the end of 2011. Individuals who developed metabolic disorders during the follow-up period were identified.ResultsThe unaffected siblings of schizophrenia probands had a higher prevalence of T2DM (3.4% vs. 2.6%, p = 0.010) than the controls. Logistic regression analyses with the adjustment of demographic data revealed that the unaffected siblings of patients with schizophrenia were more likely to develop T2DM (odds ratio [OR]: 1.39, 95% confidence interval [CI]: 1.10–1.75) later in life compared with the control group. Moreover, only female siblings of schizophrenia probands had an increased risk of hypertension (OR: 1.47, 95% CI: 1.07–2.01) during the follow-up compared with the controls.DiscussionThe unaffected siblings, especially sisters, of schizophrenia probands had a higher prevalence of T2DM and hypertension compared with the controls. Our study revealed a familial link between schizophrenia and T2DM in a large sample. Additional studies are required to investigate the shared pathophysiology of schizophrenia and T2DM.

show abstract

Relationship Between Metabolic Syndrome and Clinical Features, and Its Personal-Social Performance in Patients with Schizophrenia

Cited by 7 publications

References 49 publications

Associated illness severity in schizophrenia and diabetes mellitus: A systematic review

Associated illness severity in schizophrenia and diabetes mellitus: A systematic review

Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups

Increased risk of type 2 diabetes among the siblings of patients with schizophrenia

Contact Info

Product

Resources

About